BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36367445)

  • 21. Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.
    Meyer AN; Modaff P; Wang CG; Wohler E; Sobreira NL; Donoghue DJ; Pauli RM
    Am J Med Genet A; 2021 Mar; 185(3):798-805. PubMed ID: 33368972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
    Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
    J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L
    Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vosoritide: First Approval.
    Duggan S
    Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
    Sarabipour S; Hristova K
    Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
    Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.
    Komla-Ebri D; Dambroise E; Kramer I; Benoist-Lasselin C; Kaci N; Le Gall C; Martin L; Busca P; Barbault F; Graus-Porta D; Munnich A; Kneissel M; Di Rocco F; Biosse-Duplan M; Legeai-Mallet L
    J Clin Invest; 2016 May; 126(5):1871-84. PubMed ID: 27064282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Volumetric Bone Mineral Density, Bone Microarchitecture, and Bone Strength in Patients with Achondroplasia Caused by FGFR3 c.1138G > A Mutation.
    Liang H; Qi W; Jin C; Pang Q; Liu W; Jiang Y; Wang O; Li M; Xing X; Pan H; Xia W
    Calcif Tissue Int; 2023 Jan; 112(1):13-23. PubMed ID: 36261652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
    Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
    Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTH has the potential to rescue disturbed bone growth in achondroplasia.
    Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
    Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
    Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
    Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
    Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
    Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achondroplasia.
    Horton WA; Hall JG; Hecht JT
    Lancet; 2007 Jul; 370(9582):162-172. PubMed ID: 17630040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p.Ser348Cys mutation in FGFR3 gene leads to "Mild ACH /Severe HCH" phenotype.
    Bengur FB; Ekmekci CG; Karaarslan E; Gunoz H; Alanay Y
    Eur J Med Genet; 2020 Feb; 63(2):103659. PubMed ID: 31048079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
    Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
    Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanding horizons of achondroplasia treatment: current options and future developments.
    Fafilek B; Bosakova M; Krejci P
    Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
    Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
    Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.